SIM
CMTA

Spark Investment Management’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Spark Investment Management’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-24,300
Closed -$410K – 873
2017
Q3 		$410K Buy
+24,300
New +$397K 0.02% 512

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Spark Investment Management's CMTA Position: Q4 2017 in Review

Spark Investment Management sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q4 2017, closing a stake of 24,300 shares — an estimated $410K sold.

Spark Investment Management first reported a position in CMTA in Q3 2017 and held it in 1 quarter. The position peaked at $410K in Q3 2017. 37 funds tracked by Wall St. Rank hold CMTA as of Q4 2017.

  • Spark Investment Management reported no remaining Clementia Pharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
  • Spark Investment Management sold 24,300 Clementia Pharmaceuticals Inc. shares in Q4 2017, an estimated $410K.
  • Spark Investment Management first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 1 quarter.
  • Spark Investment Management's Clementia Pharmaceuticals Inc. position peaked at $410K in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q4 2017.

Based on Spark Investment Management's 13F filing for Q4 2017, filed 12 Feb 2018.